Arjuna Therapeutics

www.arjunatherapeutics.com ↗ ·A Coruña ·Seed

Arjuna Therapeutics is a biotechnology company based in Milladoiro, A Coruña, developing cancer treatments on its Therapeutic Molecular Clusters (TMC) platform. The platform produces orally available small molecules that act as catalysts inside cells. Its lead candidate, Ag5, is a cluster of five silver atoms that targets cancer mitochondria in solid tumours with high levels of reactive oxygen species, including glioblastoma and KRAS-mutant cancers, and is being prepared for first human trials in 2027. The company was relaunched in 2019 from NANOGAP Therapeutics as a spin-out linked to the University of Santiago de Compostela, with scientific co-founders Arturo López Quintela and Fernando Domínguez. It has seed funding from NANOGAP, a Capital Cell equity crowdfunding round of about €571,000 from 179 investors in 2024-2025, and non-dilutive grants including funding from Brain Research UK for work with the University of Oxford.

Founded

2019

Founders

Total funds raised

€2.1M

SectorsBiotechnology, Oncology, Therapeutics, Nanomedicine Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Arturo López Quintela

Scientific Co-Founder

Fernando Domínguez

Scientific Co-Founder

Global models 5

Relay Therapeutics

United States · relaytx.com ↗

Platform biotech that designs precision small-molecule cancer drugs in-house and funds them through venture money and partnerships until clinical proof, the same model as Arjuna's TMC platform.

$520MComparable

Erasca

United States · www.erasca.com ↗

Venture-backed oncology biotech building small-molecule drugs for RAS/MAPK-driven (including KRAS-mutant) solid tumours, the same kind of target Arjuna goes after with Ag5.

$450MComparable

Revolution Medicines

United States · www.revmed.com ↗

Grew from a venture-funded platform company into a KRAS-mutant cancer drug developer with oral small molecules, the route Arjuna is following for its KRAS indication.

$250MComparable

Rafael Pharmaceuticals

United States · rafaelholdings.com ↗

Privately funded developer of devimistat, a small molecule that attacks cancer-cell mitochondrial metabolism, which is closely matched to Ag5's approach of targeting mitochondria.

$200MComparable

Nanobiotix

France · www.nanobiotix.com ↗

Venture-backed biotech whose first-in-class cancer product is built on inorganic metal (hafnium oxide) particles, like Arjuna's silver-atom clusters, with value created through clinical milestones and licensing.

$150MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 2

Open as list →

Capital Cell

capitalcell.com

2 rounds · 2022–25 Spain

NANOGAP

www.nanogap.es ↗

Led Seed 2022 Spain

Funding rounds 2

Date	Round	Amount	Lead
2025-01-09	Seed	€571K	Lead not disclosed +1 more
2022-12-02	Seed (estimated)	€1.5M	Nanogap +1 more

News 4

Open as list →

Published	Article
2026-03-30	Arjuna Enters Strategic Collaboration With Pangaea Oncology And The Dr. Rosell Oncology Institute ↗ PRLog (Arjuna Therapeutics press release) 2026-03-30
2026-02-05	ARJUNA Therapeutics Partner with Oxford Researchers to Tackle Paediatric Brain Cancer ↗ PRLog (Arjuna Therapeutics press release) 2026-02-05
2025-04-04	New efficacy data for ARJUNA Therapeutics Ag5 to be presented at the 2025 AACR Meeting ↗ PRLog (Arjuna Therapeutics press release) 2025-04-04
2024-05-23	ARJUNA Therapeutics Awarded Prize at the 2024 MATWIN Congress ↗ PRLog (Arjuna Therapeutics press release) 2024-05-23